Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026)

Scholar Rock Holding's (SRRK) quarterly Liabilities and Shareholders Equity came in at $535.3 million in Q1 2026, up 31.33% year-on-year from $407.6 million in Q1 2025, and up 32.4% quarter-over-quarter from $404.3 million in Q4 2025.

Scholar Rock Holding (SRRK) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends

Scholar Rock Holding's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $535.3 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 31.33% year-over-year to $535.3 million in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 31.26% increase from a year earlier, with the FY2025 full-year figure at $404.3 million, down 14.88% from the prior year.
  • Liabilities and Shareholders Equity improved to $535.3 million in Q1 2026 per SRRK's latest filing, from $404.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $535.3 million in Q1 2026 and bottomed at $179.1 million in Q3 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $340.0 million (2025), against an average of $343.9 million.
  • Across the five-year window, Liabilities and Shareholders Equity tumbled 35.77% in 2023 and jumped 129.84% in 2025, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $358.2 million in 2022, then slipped by 13.16% to $311.0 million in 2023, then jumped by 52.69% to $474.9 million in 2024, then slipped by 14.88% to $404.3 million in 2025, then surged by 32.4% to $535.3 million in 2026.
  • Per Business Quant, the three latest SRRK Liabilities and Shareholders Equity figures stand at $535.3 million (Q1 2026), $404.3 million (Q4 2025), and $411.7 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Scholar Rock Holding 6.30 Bn 6.30 Bn - 535.25 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 535.25 Mn
Dec 31, 2025 404.27 Mn
Sep 30, 2025 411.72 Mn
Jun 30, 2025 340.05 Mn
Mar 31, 2025 407.55 Mn
Dec 31, 2024 474.92 Mn
Sep 30, 2024 179.13 Mn
Jun 30, 2024 226.87 Mn
Mar 31, 2024 267.29 Mn
Dec 31, 2023 311.04 Mn
Sep 30, 2023 250.69 Mn
Jun 30, 2023 284.90 Mn
Mar 31, 2023 314.72 Mn
Dec 31, 2022 358.17 Mn
Sep 30, 2022 390.30 Mn
Jun 30, 2022 424.13 Mn
Mar 31, 2022 265.98 Mn
Dec 31, 2021 304.45 Mn
Sep 30, 2021 298.39 Mn
Jun 30, 2021 332.05 Mn